



PTO/SB/C8a/b (08-03)  
Approved for use through 07/31/2008. OMB C851-C031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/090440		
		Filing Date	March 4, 2002		
		First Named Inventor	Grant McFadden		
		Art Unit	1642		
		Examiner Name	M. Yu		
Sheet	1	of	2	Attorney Docket Number	MDSP-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
my	AA	US-5,283,173	02-01-1994	Fields et al.	
	AB	US-5,580,736	12-03-1996	Brent et al.	
	AC	US-5,610,015	03-11-1997	Wickens et al.	
	AD	US-5,695,941	12-09-1997	Brent et al.	
	AE	US-5,955,280	09-21-1999	Vidal et al.	
	AF	US-5,965,368	10-12-1999	Vidal et al.	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
my	CA	Barry, M., et al., "The Myxoma Virus M-T4 Gene Encodes a Novel RDEL-Containing Protein that is Retained within the Endoplasmic Reticulum and is Important for the Productive Infection of Lymphocytes," <i>Virology</i> , 239:360-377 (1997).			
	CB	Bartel, et al., "Elimination of False Positives That Arise in Using the Two-Hybrid System," <i>BioTechniques</i> , 14(6):920-924 (1993).			
	CC	Cheng, E.H.Y., et al., "Bax-independent inhibition of apoptosis by Bcl-xL," <i>Nature</i> , 379:554-556 (1996).			
	CD	Chittenden, T., et al., "A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions," <i>EMBO J.</i> 14:5589-5596 (1995).			
	CE	Graham, K.A., et al., "Myxoma Virus M11L ORF Encodes a Protein for Which Cell Surface Localization Is Critical in Manifestation of Viral Virulence," <i>Virology</i> , 191:112-124 (1992).			✓
	CF	Iwabuchi, K., et al., "Use of the two-hybrid system to identify the domain of p53 involved in oligomerization," <i>Oncogene</i> , 8:1693-1696 (1993).			✓
	CG	Macen, J.L., et al., "Expression of the Myxoma Virus Tumor Necrosis Factor Receptor Homologue (T2) and M11L Genes is Required to Prevent Virus-Induced Apoptosis in Infected Rabbit T Lymphocytes," <i>Virology</i> , 218:232-237 (1996).			✓
	CH	Madura, K., et al., "N-recogin/Ubc2 Interactions in the N-end Rule Pathway," <i>J. Biol. Chem.</i> , 268:12046-54 (1993).			
	CI	McFadden, G. and Barry, M., "How Poxviruses Oppose Apoptosis," <i>Semin. Virol.</i> , 8:429-442 (1998).			
	CJ	Mossman, K., et al., "Disruption of M-T5, a Novel Myxoma Virus Gene Member of the Poxvirus Host Range Superfamily, Results in Dramatic Attenuation of Myxomatosis in Infected European Rabbits," <i>J. Virol.</i> , 70(7):4394-4410 (1996).			

Examiner Signature	<i>Michael Z</i>	Date Considered	3-19-05
-----------------------	------------------	--------------------	---------

9648998\_1



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/090440
				Filing Date	March 4, 2002
				First Named Inventor	Grant McFadden
				Art Unit	1642
				Examiner Name	M. Yu
				Attorney Docket Number	MDSP-P01-002
Sheet	2	of	2		

317	CK	Muchmore, S.W., et al., "X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death," Nature, 381:335-341 (1996).	
	CL	Oltvai, Z.N. and Korsmeyer, S.J., "Checkpoints of Dueling Dimers Foil Death Wishes," Cell, 79:189-192 (1994).	
	CM	Opgenorth, A., et al., "Deletion Analysis of Two Tandemly Arranged Virulence Genes in Myxoma Virus, M11L and Myxoma Growth Factor," J. Virol., 66(8):4720-4731 (1992).	
	CN	Yin, X.M., et al., "BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax," Nature, 369:321-323 (1994).	
	CO	Zervos, A.S., et al., "Mxi1, a Protein That Specifically Interacts with Max to Bind Myc-Max Recognition Sites," Cell, 72:223-232 (1993).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Musich</i>	Date Considered	3-19-05
--------------------	---------------	-----------------	---------

9648998\_1